Jushi (OTCMKTS:JUSHF) vs. IceCure Medical (NASDAQ:ICCM) Head-To-Head Survey

IceCure Medical (NASDAQ:ICCM) and Jushi (OTCMKTS:JUSHF) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, risk, profitability, valuation, dividends, institutional ownership and analyst recommendations.

Earnings and Valuation

This table compares IceCure Medical and Jushi”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IceCure Medical	$3.38 million	2.26	-$15.06 million	($8.52)	-0.26
Jushi	$262.91 million	0.32	-$68.59 million	($0.34)	-1.22

IceCure Medical has higher earnings, but lower revenue than Jushi. Jushi is trading at a lower price-to-earnings ratio than IceCure Medical, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

IceCure Medical has a beta of 0.45, suggesting that its share price is 55% less volatile than the S&P 500. Comparatively, Jushi has a beta of -0.63, suggesting that its share price is 163% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for IceCure Medical and Jushi, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IceCure Medical	2	0	3	0	2.20
Jushi	0	0	1	0	3.00

IceCure Medical presently has a consensus price target of $52.50, indicating a potential upside of 2,254.26%. Given IceCure Medical’s higher probable upside, equities research analysts plainly believe IceCure Medical is more favorable than Jushi.

Profitability

This table compares IceCure Medical and Jushi’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
IceCure Medical	-427.67%	-174.26%	-112.58%
Jushi	-24.44%	N/A	-15.46%

Insider & Institutional Ownership

0.6% of IceCure Medical shares are held by institutional investors. Comparatively, 21.7% of Jushi shares are held by institutional investors. 2.4% of IceCure Medical shares are held by insiders. Comparatively, 23.1% of Jushi shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Jushi beats IceCure Medical on 8 of the 14 factors compared between the two stocks.

About IceCure Medical

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense system, a single probe system; and MultiSense, a multi probe system for the treatment of multiple and larger tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.

About Jushi

Jushi Holdings Inc., a vertically integrated cannabis company, engages in the cultivation, processing, retail, and distribution of cannabis for medical and adult-use markets. The company offers flower, extracts, concentrates, edibles, oil, pre-rolls, tinctures, capsules, softgels, cannabis-infused gummies and ultra-premium chocolate, and topicals products, as well as vaporization devices and cartridges under The Bank, The Lab, Nira+ Medicinals, Sèchè, Tasteology, and Hijinks brands. It is also involved in the bulk wholesale of refined cannabinoids and terpenes. In addition, the company operates medical cannabis dispensaries under the BEYOND/HELLO, Nature’s Remedy, and NuLeaf brands. It markets its products to local dispensaries and large multi-state operators. The company is headquartered in Boca Raton, Florida.